Trial Profile
A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications Betacoronavirus infections; COVID 2019 infections; Enterovirus infections; Hypoxaemia; Influenza virus infections; Metapneumovirus infections; Parainfluenza virus infections
- Focus Therapeutic Use
- Acronyms STOP-Flu
- Sponsors Ansun Biopharma
- 16 Aug 2023 Results published in the Clinical Infectious Diseases
- 08 Jul 2020 Planned initiation date changed from 1 Apr 2020 to 1 Jul 2020.
- 01 Apr 2020 Planned initiation date changed from 1 Mar 2020 to 1 Apr 2020.